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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYIsolation of ventricular cardiomyocytes (vCMs) has been challenging due to the lack of specific surfacemarkers. Here we show that vCMs
can be purified from differentiating mouse embryonic stem cells (mESCs) using molecular beacons (MBs) targeting specific intracellular
mRNAs. We designed MBs (IRX4 MBs) to target mRNA encoding Iroquois homeobox protein 4 (Irx4), a transcription factor specific for
vCMs. To purify mESC vCMs, IRX4 MBs were delivered into cardiomyogenically differentiating mESCs, and IRX4 MBs-positive cells
were FACS-sorted.We found that, of the cells isolated,98%displayed vCM-like action potentials by electrophysiological analyses. These
MB-purified vCMs continuously maintained their CM characteristics as verified by spontaneous beating, Ca2+ transient, and expression
of vCM-specific proteins. Our study shows the feasibility of isolating pure vCMs via cell sorting without modifying host genes. The ho-
mogeneous and functional ventricular CMs generated via the MB-based method can be useful for disease investigation, drug discovery,
and cell-based therapies.INTRODUCTION
Heart failure is the leading cause of death worldwide; how-
ever, current therapies such as surgical interventions are
capable only of delaying the progression of this devastating
disease (Go et al., 2013). In particular, patients suffering
frommyocardial infarction (MI), amajor cause of heart fail-
ure, have cardiac dysfunction due to significant loss of
cardiomyocytes (CMs) (Laflamme and Murry, 2011). The
adult mammalian heart has very limited ability to regen-
erate after such a loss.
Due to their self-renewal and multi-lineage differentia-
tion capacity, embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs), collectively called pluripo-
tent stem cells (PSCs), have emerged as a highly promising
and renewable source for generating CMs (Kehat et al.,
2001; Laflamme et al., 2007; Yang et al., 2008; Zwi et al.,
2009). Studies have shown that cell cultures directed to-
ward differentiation into CMs include three types of
CMs, nodal, atrial, and ventricular CMs, in varying ratios
as well as other lineage cells (Huber et al., 2007; Lian
et al., 2012; Shiba et al., 2012; Tohyama et al., 2013).
Each type of cardiac-chamber-specific CMhas unique func-
tional, structural, and electrophysiological characteristics
(Ng et al., 2010). Thus, transplantation of cardiomyogeni-
cally differentiated cells, which include heterogeneous
CMs and other lineage cells, into injured myocardiumStem Cell Repmight induce dysrhythmia, asynchronous cardiac contrac-
tion, or aberrant tissue formation (Liao et al., 2010). Since
ventricular CMs are the most extensively affected cell
type inMI and themajor source for generating cardiac con-
tractile forces, there has been great interest in producing
ventricular CMs from stem cells for treatment of MI (Bizy
et al., 2013; Lee et al., 2012; Mu¨ller et al., 2000; Zhang
et al., 2011). It would therefore be ideal to generate a pure
population of ventricular CMs from PSCs for cardiac-cell-
based therapies.
Despite the unmetmedical need, to date, no studies have
demonstrated the feasibility of isolating ventricular CMs
without permanently altering their genome. Prior studies
used genetic modification for isolating ventricular CMs
by inserting a fluorescent reporter gene driven by the
MYL2 (or MLC-2v) promoter into mouse ESCs and embry-
onic carcinoma cell lines (Bizy et al., 2013; Lee et al., 2012;
Mu¨ller et al., 2000; Zhang et al., 2011). Such genetic modi-
fication precludes clinical use of the isolated cells due to
concerns of tumorigenicity or adverse reactions. These
ventricular CMs would not be appropriate for drug devel-
opment or diseasemodeling due to the random and perma-
nent changes in the genome or the use of viral vectors.
Further, there are no known surface markers specific for
ventricular CMs, disallowing antibody-based cell sorting
with flow cytometry, which is the most common method
for isolating targeted cells from differentiating PSCs.orts j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 The Authors 1239
Figure 1. Selection of Optimal Ventricu-
lar Cardiomyocyte-Specific IRX4 Molecu-
lar Beacons
(A) Irx4 mRNA structure was predicted us-
ing the RNAfold web server. Three unique
target sequences were identified in Irx4
mRNA that maximized the number of pre-
dicted unpaired bases as well as the binding
affinity of a complementary probe.
(B) Stem sequences were appended to the
complementary sequence and evaluated
using QUIKFOLD to minimize the free en-
ergy that causes the oligonucleotide to
assume a hairpin structure in solution.
(C–E) Flow cytometry results after deliv-
ering various IRX4 MBs designed to identify
Irx4 mRNAs, or control MB, into mouse
embryonic fibroblasts (C), eonatal mouse
ventricular CMs (D), and HL-1 CMs (E). The
number in each panel represents the per-
centage of fluorescent cells. FSC indicates
forward scatter. All experiments were per-
formed on three independent biological
replicates (C–E).Although not surface markers, several genes are known
to be specifically expressed in ventricular hearts or CMs.
As a ventricular-specific transcription factor, Iroquois
homeobox protein 4 (IRX4) has been reported to be exclu-
sively expressed in the ventricular myocardium while ab-
sent from both atria and the outflow tract (Bao et al.,
1999). IRX4 positively regulates ventricular-chamber-spe-
cific gene expression by activating the ventricular myosin
heavy chain-1 (VMHC1) gene while suppressing the
expression of atrial myosin heavy chain-1 (AMHC1) (Bru-
neau et al., 2000;Wang et al., 2001). As a structural protein,
MYL2 (or MLC-2v), one of the essential MLC-2 isoforms
that is important for the contractile function of ventricular
CMs, is expressed in ventricular CMs (Marionneau et al.,
2005; O’Brien et al., 1993). MYL2 expression is mostly
restricted to the ventricular segment of the heart withmin-
imal expression in the outflow track during cardiogenesis
(Kubalak et al., 1994; O’Brien et al., 1993).
Accordingly, we have developed a method targeting an
intracellular gene to purify ventricular CMs. We used a
molecular beacon (MB)-based method for isolating a pure
population of ventricular CMs by targeting the mRNA of
the ventricular-specific transcription factor IRX4 (Figures
1A and 1B). MBs are 20- to 30-bp oligonucleotide probes
with a fluorophore and a quencher at the 50 and 30 ends,
respectively (Figures 1A and 1B) (Heyduk and Heyduk,
2002). They are designed to form a stem-loop (hairpin)
structure so that the fluorophore and quencher are within
close proximity and fluorescence is quenched. Hybridiza-
tion of the MBs with the target mRNA opens the hairpin1240 Stem Cell Reports j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 Thstructure and physically separates the fluorophore from
the quencher, allowing a fluorescence signal to be emitted
upon excitation (Tsourkas et al., 2002). It has been demon-
strated that cellular delivery of MBs does not alter the
expression level of the target genes (Rhee and Bao, 2009;
Rhee et al., 2008; Santangelo et al., 2006; Tsourkas et al.,
2002), andMBs can be used to isolatemESCs by directly tar-
geting specific intracellular mRNAs such as Oct4 (Rhee and
Bao, 2009). Further, we demonstrated that MBs enable the
enrichment of general CMs fromdifferentiatingmouse and
human PSCs (Ban et al., 2013).
In the present study, we developed a sophisticated
approach using MBs targeting transcription factor mRNAs,
which, due to their low copy numbers compared to struc-
tural protein mRNAs, are highly challenging and were
not previously attempted. By designing specificMBs target-
ing Irx4 mRNA, we show here that functional ventricular
CMs derived from differentiating mouse ESCs could be iso-
lated with high purity. TheMB-based cell isolationmethod
is quite versatile; a wide range of specific intracellular
mRNAs could be targeted to achieve high specificity,
including mRNAs encoding structural proteins and tran-
scription factors.RESULTS
Ventricular Cardiomyocyte-Specific Gene Selection
Through an extensive literature search, we selected Irx4 as a
target gene for generating ventricular CM-specificMBs (Baoe Authors
Table 1. IRX-4 MB Designs
Beacon Design Beacon Sequence (50–30)a Target Sequence (50–30)
IRX4-1 Cy3-CACCTAGTTTTGTTATATTAGCCTCCCTAGGTG-BHQ2 AGGGAGGCTAATATAACAAAAC
IRX4-2 Cy3-CCCTGACGTAAACTTTATGCTTCAGGG-BHQ2 CCCTGAAGCATAAAGTTTACGTC
IRX4-3 Cy3-CAGGCAGAGAGTAGAAAGCAGATGCCTG-BHQ2 AGGCATCTGCTTTCTACTCTCTG
Control MB Cy3-ACGACGCGACAAGCGCACCGATACGTCGT-BHQ2 GTATCGGTGCGCTTGTCGCG
aUnderlined bases indicate the arms forming the stem.et al., 1999; Bruneau et al., 2000; Wang et al., 2001). First,
we measured mRNA expression levels of Irx4 via qRT-PCR
analysis in CMs isolated from either ventricles or atria of
mouse adult hearts. We also measured Myl2, which is a
well-defined ventricular CM-specific gene, as a positive
control. The results showed that Irx4 was robustly ex-
pressed in ventricular CMs, but not atrial CMs (Figure S1A).
The expression levels of both Irx4 and Myl2 mRNAs were
substantially higher in mouse ventricular CMs compared
to atrial CMs, indicating that Irx4 is a viable target for MB
selection.
Generation of IRX4 MBs
We designed three IRX4 MBs targeting distinct sites in the
mouse Irx4 mRNA using design rules validated in our pre-
vious publications (Figures 1A and 1B) (Ban et al., 2013;
Rhee et al., 2008; Tsourkas et al., 2002). In addition, we
used mFold (Zuker, 2003) and the RNA Composer Web-
server (Popenda et al., 2012) to model the IRX4MB designs
and to predict the accessibility of hybridization sites in the
target mRNAs. These IRX4 MBs were synthesized with a
Cy3 fluorophore on the 50 end and a Black Hole Quencher
2 (BHQ2) on the 30 end as specified in Table 1. We quanti-
fied MB fluorescence signals when hybridized to perfectly
complementary or mismatched synthetic DNA targets by
incubating 500-nM MBs in solution with increasing con-
centrations (60–500 nM) of DNA targets. IRX4 MB signals
were recorded using a microplate reader and normalized
by the background signals in wells with MBs only. All
IRX4MBs displayed a linear response to increasing concen-
trations of complementary targets and low signal levels
when mismatched targets were used (Figure S1B).
Delivery of MBs into Different Cell Types
After testing several different methods for cellular delivery
of MBs, we found that the use of a Nucleofector (Lonza)
with Nucleofection Solution V and program A033 was an
efficient method (up to 99%) to deliver MBs to a variety
of cell types (Ban et al., 2013). To further refine this
approach, we also designed two distinct MBs as controls.
The first was a non-specific interaction indicator MB (RQ)
that contained a 20-bp loop sequence given by randomStem Cell Repwalk, which did not have any perfect matches in the entire
mouse genome. Therefore, any fluorescence resulting from
this control MB would be non-specific signal. The second
was a delivery control MB (UQ) with the same random
sequence, but it did not contain a quencher, so it fluoresced
at all times. Both RQ and UQMBs were delivered to cells to
ensure that delivery was efficient and that MB signal was
specific to the target mRNA sequence.
Selection of Optimal IRX4 MB for Isolating
Ventricular-like Cardiomyocytes
In order to select the best MB to efficiently identify and
isolate ventricular CMs, we examined the specificity, sensi-
tivity, and reliability of each IRX4 MB in three separate
systems. To determine the specificity of MBs, we used nu-
cleofection to deliver each of the three IRX4 MBs into
mouse embryonic fibroblasts (mEFs), which do not express
IRX4, and analyzed the cells that showed false-positive
signals using flow cytometry. We found that among
the three MB designs (IRX4-1, IRX4-2, and IRX4-3) exam-
ined, IRX4-1 and IRX4-2 MBs yielded significantly fewer
false-positive cells from mEFs (IRX4-1: 0.9% ± 0.1%, and
IRX4-2: 1.4% ± 0.1%) than IRX4-3 MB (40.6% ± 3.8%).
Hence, only IRX4-1 and IRX4-2 MBs were selected for
further experiments (Figure 1C). To evaluate the detection
sensitivity of IRX4-1 and IRX4-2 MBs, each was delivered
into mouse neonatal ventricular CMs and analyzed with
flow cytometry. IRX4-2 MBs resulted in a substantially
higher percentage of ventricular CMs (85.8% ± 3.7%)
compared to IRX4-1 MBs (17.9% ± 2.1%). On the basis of
these results, we selected IRX4-2 MB as the probe for en-
riching mESC-derived ventricular CMs (Figure 1D).
To further confirm detection specificity, we delivered the
IRX4-2MB to HL-1 CMs, an immortalized mouse atrial CM
cell line known to retain atrial CM characteristics (Brundel
et al., 2006; Claycomb et al., 1998). Flow cytometry anal-
ysis showed that less than 2% of HL-1 CMs displayed a pos-
itive signal from IRX4-2 MBs, providing additional support
for the high specificity of IRX4-2 MB in isolating ventricu-
lar CMs (Figure 1E). We also tested the IRX4-2 MB against
themost likely contaminating cell types in cardiomyogeni-
cally differentiated PSC cultures: mouse smooth muscleorts j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 The Authors 1241
Figure 2. Purification of Ventricular Cardiomyocytes from
Differentiating mESCs through IRX4-2 MBs
(A) A schematic of the protocol to differentiate mESCs to the car-
diac lineage. ESCs, mouse embryonic stem cells; EBs, embryoid
bodies.
(B) Flow cytometric scattergrams showing the percentages of cells
expressing both TNNT2 and MYL2 at differentiation day 18.
(C) A flow cytometry plot showing IRX4-2-MB-positive cells at
differentiation day 18.
(D) Flow cytometric scattergrams showing the percentages of
cells expressing both TNNT2 and MYL2 after FACS sorting with
IRX4-2 MB.
All experiments were performed on three (B and D) or six (C) in-
dependent biological replicates.cells (SMCs), mouse aortic endothelial cells (mECs), mouse
cardiac fibroblasts (mCFs), and mESCs (Figure S1C). Flow
cytometry analysis showed that less than 3% of those cells
displayed detectable fluorescence signals. These results
clearly demonstrated that the IRX4-2 MB is specific for
identifying ventricular CMs.
Generation of Ventricular CMs from Mouse ESCs
To ensure stable production of mESC-derived ventricular
CMs, we first established an embryoid body (EB)-mediated
CM differentiation system (Figure 2A). Undifferentiated
mouse ESCs (J1) maintained on STO feeder cells were enzy-
matically detached to form EBs. Since EB-induced differen-1242 Stem Cell Reports j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 Thtiation alone is not sufficient to produce a high percentage
of CMs, we plated day-4 EBs into a fibronectin-coated dish
and added ascorbic acid (50 mg/ml) to enhance CM differ-
entiation. Spontaneously beating clumps began to appear
3–4 days after plating (Takahashi et al., 2003) (Movie S1).
After 7 days of CM differentiation on monolayer cultures,
we enzymatically dissociated the cells and applied them
to a discontinuous Percoll gradient (40.5% to 58.5%) to
enrich mESC-derived CMs (Xu et al., 2002). Percoll-medi-
ated separation typically produces three layers of cells,
and the bottom layer was reported to include a higher per-
centage of CMs. Thus, the cells in the bottom layer were
collected and cultured for another 7 days in the presence
of cyclosporine A (30 mg/ml) to further induce CMdifferen-
tiation (Fujiwara et al., 2011). Finally, we applied IRX4MBs
to these 18-day cultured mESC-derived CMs.
qRT-PCR analysis revealed dynamic changes in the ex-
pression of CM-specific genes in our differentiation system,
indicative of efficient CM differentiation. Expression of
cardiac contractile genes (Tnnt2 and Myh7) and genes for
atrial (Myl7) and ventricular (Myl2 and Irx4) CMs began
to appear 7 days after culture. Expression of Myl2 and Irx4
continuously increased until day 18 (Figure S2A).
We next carried out immunocytochemistry and flow cy-
tometry to further characterize the cell population at day
18. Immunocytochemistry demonstrated that day-18 cells
significantly expressed CM-specific proteins, including
ACTN2 (a-sarcomeric actinin), TNNT2 (cardiac troponin
T), andMYH6/7 (a and bmyosin heavy chain), confirming
their CM nature (Figure S2B). A substantial number of cells
that were positive for ACTN2, TNNT2, and MYH6/7
concomitantly expressed MYL2 (or MLC2V), which is
a specific protein for ventricular CMs. At day 18, the
percentages of cells expressing TNNT2 or MYL2 were
67.9% ± 4.5% and 39.2% ± 3.8%, respectively (Figure S3A),
and 35.5% ± 4.1% of cells expressed both TNNT2 and
MYL2 (Figure 2B). These results clearly indicate efficient
generation of CMs, with a significant percentage of ventric-
ular CMs, through our CM differentiation system.
Purification of mESC-Derived Ventricular CMs
through IRX4-2 MBs
After establishing the CM differentiation system, we
delivered IRX4-2-MB to the 18-day differentiated cells
to isolate ventricular CMs. We used a pre-validated nucleo-
fection protocol to deliver MBs and sorted the cells by fluo-
rescence-activated cell sorting (FACS). Flow cytometry
results showed that 41.3% ± 5.8% of cells were positive
for fluorescence signal from IRX4-2 MB (Figure 2C). This
number is similar to the detection rate (39.2% of Myl2-
positive cells) of ventricular CMs using antibody-based
methods. We then conducted FACS sorting based on
IRX4-2-MB signal, and the MB-positive CMs were seedede Authors
onto fibronectin-coated plates for further experiments. The
IRX4-2-MB-positive CMs began to beat spontaneously
within 48 hr and continued to beat vigorously for up to
2 weeks (Movie S2). Only a small number of IRX4-2-MB-
negative cells showed beating (data not shown).
To determine the cell viability after IRX4-2-MB-based cell
sorting, we performed a propidium iodide (PI)-based cell
viability assay (Chan et al., 2012; Sasaki et al., 1987). To
this end, two groups of cells were treated with PI: one group
that underwent FACS sorting with IRX4-2 MB transfection
and the other without IRX4-2 MB transfection. Then, we
performed flow cytometry to measure the PI-negative, or
viable, cells. Flow cytometry analyses showed that 55.5%
of the IRX4-2-MB-transfected group was PI negative as was
63.4% of the group without IRX4-2 MB transfection (Fig-
ure S3B), suggesting 8% cell damage caused by MBs.
Two days after FACS sorting, we conducted flow cytome-
try analyses using TNNT2 andMYL2 antibodies to quantify
the percentage of CMs and ventricular-like CMs in IRX4-2-
MB-positive cells. The percentage of cells expressing either
TNNT2 or MYL2 was 97.2% ± 3.4% or 91.6% ± 5.1%,
respectively (Figure S3C), and that expressing both
TNNT2 andMYL2was 91.3% ± 2.8% (Figure 2D). Together,
these results indicate efficient enrichment ofmESC-derived
ventricular CMs by IRX4-MB-based cell sorting.
Electrophysiological Characteristics of IRX4 MB+
Ventricular-like CMs
To investigate the electrophysiological characteristics
of IRX4-2-MB-positive and -negative CMs, we performed
whole-cell patch clamp analyses (Figure 3A). It is known
that the action potential duration (APD) is longer inmouse
fetal ventricular CMs than in atrial CMs (Figure 3A) (Hume
and Uehara, 1985). Similarly, we found that IRX4-2-MB-
positive CMs displayed substantially longer APDs than
IRX4-2-MB-negative cells (Figure 3A). APD50 was also
longer in IRX4-2-MB-positive cells than in IRX4-2-MB-
negative cells (159 ± 21.7 ms versus 35 ± 7.8 ms, p < 0.01)
(Figure 3B). On the basis of these results, we found that
98% of IRX4-2-MB-positive cells possessed ventricular
type action potentials (APs) (49 out of 50 cells), which
showed electrical synchronism, whereas atrial- or nodal-
type APs were not observed in these cells (Figure 3C). Due
to the small number of contracting cardiomyocytes in
the IRX4-2-MB-negative cells, we were unable to appropri-
ately measure the APs. Alternatively, we performed immu-
nostaining to verify the identity of the IRX4-2-MB-negative
cells with CM-specific antibodies. Immunocytochemistry
demonstrated that none of the IRX4-2-MB-negative cells
expressed the ventricular CM marker MYL2, and less than
20% of them expressed ACTN2, suggesting that there are
some CMs, but no ventricular CMs, in the IRX4-2-MB-
negative population (Figure S4A).Stem Cell RepNext, we performed multielectrode arrays (MEAs) to
investigate the synchronous activities of the purified CMs.
While IRX4-2-MB-negative cells showed limited and non-
synchronous electrical activities, IRX4-2-MB-positive CMs
demonstrated regular and synchronous APs, suggesting a
well-coupled syncytium of cells with appropriate CM elec-
trophysiological characteristics in the IRX4-2-MB-positive
population. Lack of electrical activity measured in the
IRX4-2-MB-negative cellsmay be due to a higher proportion
of non-CM cell types in this population (Figure S4B).
Last, we performed real-time intracellular calcium [Ca2+]i
imaging analysis with IRX4-2-MB-sorted ventricular CMs
in comparison to fetal mouse atrial and ventricular CMs
(Figures 3D and 3E). In this analysis, all three types of
CMs showed automaticity, but the patterns of calcium
transients of IRX4-2-MB-positive CMs were similar to ven-
tricular CMs, but not to atrial CMs; the frequency was
slower and the amplitude was larger in IRX4-2-MB-positive
CMs and ventricular CMs compared to atrial CMs (Figures
3D and 3E). Collectively, these results demonstrated that
the IRX4-2-MB-positive cells possess ventricular-CM-like
electrophysiological properties.
Cellular Characterization of FACS-Sorted
Ventricular CMs
To examine the cardiac identity and homogeneity of the
ventricular CMs purified with IRX4-2 MB, immunocyto-
chemistry was conducted with antibodies against various
CM-specific markers (ACTN2, TNNT2, and MYH6/MYH7
and MYL2) and a ventricular CM marker (MYL2) 2–3 days
after FACS sorting and cell culture. As shown in Figure 4A,
immunocytochemistry demonstrated that almost all IRX4-
2-MB-isolated ventricular CMs exhibited ACTN2, TNNT2,
and MYH6/MYH7. Furthermore, a positive immunoreac-
tivity for MYL2 was found in all of the IRX4-2-MB-positive
CMs (Figure 4A). Importantly, these IRX4-2-MB-positive
CMs abundantly expressed GJA1 (known as connexin
43), an important connexin isoform in the formation of
gap junctions between ventricular CMs, indicating that
these enriched ventricular CMs possess the functional
capability of forming cardiac junctions (Figure 4B). qRT-
PCR analyses further demonstrated that expression of ven-
tricular CMgenes Irx4 andMyl2was substantially increased
in IRX4-2-MB-positive cells compared to the IRX4-2-MB-
negative cells (Figure 4C; Table S1). Furthermore, these
IRX4-2-MB-positive cells showed a significant increase in
the expression of general CM-specific genes (Tnnt2 and
Myh6/Myh7) compared to the IRX4-2-MB-negative cells
(Figure 4C). Genes representing atrial-specific CMs (Myl7)
or other cell types were either expressed at negligible levels
(Acta2, Ddr2, and MyoD) or were non-detectable (Pecam1
and Neuro D) in the IRX4-2-MB-positive cells (Figure 4C
and data not shown).orts j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 The Authors 1243
Figure 3. Electrophysiological Characteristics of IRX4-2-MB-Purified Ventricular Cardiomyocytes
(A) Representative action potentials of IRX4-2-MB-positive and -negative cells (upper panel) and primarily isolated mouse fetal ven-
tricular and atrial cardiomyocytes (lower panel).
(B) Half action potential duration (APD50) of IRX4-2-MB-positive and -negative cells and mouse fetal ventricular and atrial car-
diomyocytes.
(C) The percentages of the action potential types recorded from IRX4-2-MB-positive cells. A-like, atrial-like AP; V-like, ventricular-like AP.
Action potentials were measured from 50 cells in each group (A–C).
(D) Representative spontaneous calcium transients in IRX4-2-MB-positive cardiomyocytes (upper panel), mouse primary fetal ventricular
cardiomyocytes (middle panel), and mouse primary fetal atrial cardiomyocytes (lower panel). In each panel, calcium transients were
recorded in the upper section, where increasing calcium is indicated by the change in color from dark blue to light blue, and fluorescence
intensity was normalized to the baseline measured at time 0 (Fo).
(E) The averages of the beating frequency (BPM) and calcium amplitude (F/F0) of IRX4-2-MB-positive cells and mouse fetal ventricular and
atrial cardiomyocytes.
Calcium transient experiments were performed on 15 cells in each group (D and E).Taken together, our results clearly demonstrated that
IRX4-2 MBs targeting ventricular CM-specific mRNA in
living cells enabled the isolation of functional ventricular
CMs from differentiating mESCs with high specificity
and efficiency.DISCUSSION
Over the past decade, there has been notable advancement
in the methodologies for generating PSCs (Takahashi et al.,
2007; Takahashi and Yamanaka, 2006) and producing CMs
from PSCs, raising the prospects of using stem-cell-derived
CMs for cardiac repair (Laflamme et al., 2007; Yang et al.,
2008). However, all reported CM differentiation protocols1244 Stem Cell Reports j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 Thto date can generate only heterogeneous CMs mixed with
other cell populations. Although several recent studies re-
ported non-geneticmethods for isolating general CMs (Du-
bois et al., 2011; Hattori et al., 2010), these methods still
generate heterogeneous CMs, not chamber-specific CMs.
Given the major role of ventricular CMs for cardiac con-
tractile function, it is important to develop a non-genetic
method to isolate ventricular CMs from differentiating
PSCs for preclinical and clinical applications.
To address this unmet need, in this work, we designed
MBs targeting IRX4, a ventricular CM-specific transcrip-
tion factor, generated homogeneous ventricular-like CMs
from mESCs without altering their genome, and demon-
strated that this method yielded functional ventricular
CMs with high specificity and efficiency. Specifically,e Authors
Figure 4. Characterization of Purified
Ventricular CMs through IRX4-2 MBs
(A) Immunocytochemistry for ACTN2, TNNT2,
andMYH6/MYH7on IRX4-2-MB-positive cells
isolated from cardiomyogenically differenti-
ated mESCs. Scale bars, 20 mm.
(B) Expression of GJA1 determined by immu-
nocytochemistry on IRX4-2-MB-positive cells
isolated from cardiomyogenically differenti-
ated mESCs. Scale bars, 50 mm.
(C) mRNA expression of cardiac (Myh6/Myh7
and Tnnt2), ventricular (Myl2 and Irx4),
atrial (Myl7), and non-cardiac genes (Acta2,
Ddr2, and MyoD) in IRX4-2-MB-positive and
-negative cells measured by qRT-PCR. y axis
represents relative mRNA expression of
target genes to GAPDH. *p < 0.05 compared
to in IRX4-2-MB-negative cell group. Data
are represented as mean ± SEM. All experi-
ments were performed on three independent
biological replicates.nucleofection-based delivery of MBs targeting the Irx4
mRNA followed by FACS sorting enabled efficient enrich-
ment of ventricular CMs from differentiating mESCs with
92% purity. In electrophysiological studies, approximately
98% of these MB-purified CMs demonstrated ventricular-
CM-like action potentials and Ca2+ oscillations, indicating
that they are functionally intact ventricular CMs. These
cells showed coordinated contraction and maintained
their phenotype for more than 2 weeks in culture.
Our study demonstrates that specific cells could be iso-
lated with high specificity by targeting the mRNA of a
transcription factor using MBs. This marks a significant
advance of the method we developed recently, where the
use of MBs targeting the mRNA of a structural protein
(MYH) allowed sorting of general CMs from differentiating
human andmouse PSCs (Ban et al., 2013). Since themRNA
expression of a transcription factor is usually much less
abundant than that of a structural protein, it was very chal-
lenging to apply the MB-based method for the isolation of
these specific cells. In fact, we initially designedMBs target-
ing another transcription factor, NKX2.5, but theMB signal
level was not high enough for isolating CMs using FACS.
Another major challenge was to identify an optimal deliv-
ery method to internalize a large amount of MBs (e.g., >
2,000 per cell) in order to generate a sufficiently high fluo-
rescence signal when hybridized to target mRNAs. We
tested quite a few different methods to deliver MBs into
living cells, including the use of Streptolysin O, Lipofecta-
min 2000, Lullaby, microinjection, and nucleofection,
and found that nucleofection with a specific buffer solu-
tion induced the maximal target mRNA detectability with
minimal cytotoxicity (data not shown). We and othersStem Cell Rephave found that after delivery into living cells, MBs do
not affect the expression of the target mRNA or other
mRNAs (Rhee and Bao, 2009), and they degrade within a
few hours so that their effects on cell viability and cell func-
tionality are negligible (Ban et al., 2013; Chen et al., 2008;
Rhee and Bao, 2009; Rhee et al., 2008; Santangelo et al.,
2006). Even with repetitive delivery of MBs, we did not
observe phenotypic or functional changes of cells, as evi-
denced by the unaffected spontaneous contraction and
the results of immunocytochemistry assays shown in this
study.
Other RNAdetectionmethods, such as the SmartFlare sys-
tem (Halo et al., 2014; Lahm et al., 2015; Prigodich et al.,
2012) and ratiometric bimolecular beacons (RBMB) (Chen
et al., 2010; Zhang et al., 2013), have recently been devel-
oped. According to the published reports, both systems
cangenerate sufficient and specific signals to be able to iden-
tify less abundant mRNA transcripts (Chen et al., 2010;
Lahm et al., 2015). In addition, the cellular delivery of the
SmartFlare system isgenerally easydue to thenatural cellular
uptake of the nanoparticles (Halo et al., 2014; Lahm et al.,
2015; Prigodich et al., 2012).Nevertheless, themajor advan-
tages of an MB-based method over these two methods are
the entropic bonus of a singlemolecule system and the abil-
ity to rapidly iterate design parameters. Since a standardMB
is a single-molecule system, the enthalpy of the stem can be
significantly lower than the SmartFlare or RBMB systems
while still generating similar binding affinities for the target
mRNA (Chen et al., 2008; Heyduk and Heyduk, 2002). In
addition, there are a multitude of online software tools
that predict single-stranded RNA structure. The RBMB sys-
tem requires a more complicated two-molecule simulation,orts j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 The Authors 1245
and the SmartFlare system requires both a competitive bind-
ing calculation to be performed and the effect of steric hin-
drance to be considered due to the relatively large delivery
particle.
We believe that the production of homogeneous and
functional PSC-derived ventricular CMs using a non-trans-
genic approach will open new avenues for basic research
and clinical applications. First, a pure population of ven-
tricular CMs generated by the MB-based method offers a
safer and more effective option for cell therapy and tissue
engineering compared to the use of mixed populations of
PSC-derived CMs, which are more likely to cause abnormal
electrical activity (Liao et al., 2010) or less efficient contrac-
tile function (van Laake et al., 2008). From a research
perspective, the MB-purified ventricular CMs represent a
powerful in vitro tool for disease investigation and drug dis-
covery. They can be used as better-defined in vitro model
systems for genetic or idiopathic cardiac diseases such as
long QT syndrome (Itzhaki et al., 2011; Moretti et al.,
2010). They can also serve as an in vitro model to
test chamber-specific effects of candidate cardiac drugs
(Liang et al., 2013). These purified CMs will yield more ac-
curate genetic and epigenetic information through high-
throughput sequencing techniques. We anticipate that
this MB-based cell-sorting method can be adopted for
isolating other cardiac cells, such as nodal cells and atrial
CMs, and has the potential to be used in isolating other
cell types from differentiating PSCs, such as neuronal cells
and pancreatic b cells.EXPERIMENTAL PROCEDURES
MB Synthesis and Characterization
Three IRX4 MBs were synthesized by MWG Operon with high-
pressure liquid chromatography (HPLC) purification (Table 1)
(Ban et al., 2013). IRX4 MBs were re-suspended in nuclease-free
PBS buffer (pH 7.4) to minimize buffer incompatibility with cells.
IRX4 MBs were tested against synthetic 20- to 30-bp complemen-
tary sequences in PBS solution to verify their activity. To demon-
strate specificity, MBs were also tested against synthetic targets
with 6-bp mismatches.
Mouse ESC Culture and Differentiation
mESCs (J1) were maintained as described previously (Ban et al.,
2013). To differentiate mESCs into cardiac lineage, an embryoid
bodymethodwas usedwith somemodifications.More details con-
cerning the materials and methods can be found in the Supple-
mental Information.
Flow Cytometry
After nucleofection, cells were centrifuged at 1,500 rpm for 2 min,
re-suspended in DMEM/F12 basal media, and maintained on ice
for 20min to recover. Cells were then analyzed by C6 FlowCytom-
eter (BD Biosciences) or sorted using a BD FACS Aria II cell sorter1246 Stem Cell Reports j Vol. 5 j 1239–1249 j December 8, 2015 j ª2015 Th(BD Biosciences). MB signal was recorded using a 561-nm laser
with a 585/15-nm emission filter to optimally excite and detect
Cy3. For MB experiments, negative control MB (Table 1), whose
loop sequence was generated using ‘‘random walk’’ and does not
match with any mRNA sequence in the entire mouse genome,
was used as a negative control for gating. For intracellular flow cy-
tometry (TNNT2 and MYL2) analyses, isotype control antibodies
were used as negative controls for gating. Data were analyzed using
FlowJo software (Treestar).
Cell Viability Assay
FACS-sorted cells were resuspended in 1 ml of flow cytometry
staining buffer and 5 ml of PI staining solution (Sigma) to each sam-
ple just prior to analysis. Then it was mixed gently and incubated
for 1 min in the dark. PI fluorescence was determined by C6 Flow
Cytometer (BD Biosciences) using the FL-2 channel at 488-nm
laser illumination. Finally, the obtained results were compared to
unstained cells and single-color positive controls.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 10 min at room
temperature, washed twice with PBS, and permeabilized with
0.1% or 0.5% Triton X-100 in PBS for 10 min. Samples were then
blocked with 1% BSA in PBS for 60 min at room temperature and
incubated with anti-Actn2 (Sigma, #A7811; 1:100), mouse anti-
Tnnt2 (Thermo, #MS295P1; 1:100), anti-Myl2 (ProteintechGroup,
#55462-1-AP; 1:100) or Gja1 (BD, #610062; 1:100) at 4C over-
night. The cells were washed three times with 1% Tween 20 in
PBS and incubated with anti-mouse immunoglobulin G (IgG)-
Alexa Fluor 594 (Thermo, #A-11005; 1:1,000) or anti-rabbit IgG-
Alexa Fluor 488 (Thermo, # A-11008; 1:1,000) in PBS for 1 hr at
room temperature. DAPI was used for nuclear staining. The sam-
ples were visualized under a fluorescent microscope (Nikon) and
a Zeiss LSM 510 Meta confocal laser scanning microscope and
LSM 510 Image software (CLSM, Carl Zeiss).
qRT-PCR
Total RNAwas preparedwith the RNeasy PlusMini Kit (Qiagen) ac-
cording to the manufacturer’s instructions. The extracted RNA
(100 ng to 1 mg) was reverse transcribed into cDNA (reverse tran-
scription) via Taqman reverse transcription reagents, including
random hexamers, oligo (dT), and MultiScribe MuLV reverse tran-
scriptase (Applied Biosystems). qPCRwas performed on a 7500 Fast
Real-Time PCR system (Applied Biosystems) using Fast SYBRGreen
master mix (Applied Biosystems). All annealing steps were carried
out at 60C. Relative mRNA expression of target genes was calcu-
lated with the comparative CT method. All target genes were
normalized to Gapdh in multiplexed reactions performed in tripli-
cate. Differences in CT values (DCT = CT gene of interest  CT
Gapdh in experimental samples) were calculated for each target
mRNA by subtracting the mean value of GAPDH (relative expres-
sion = 2–DCT) (Kim et al., 2010). Information on primer sets (Euro-
fins) used in this study is listed in Table S1.
Intracellular Calcium Imaging
For calcium (Ca2+) imaging, IRX4-2-MB-based purified cells ESC-
CMs were plated on glass coverslips and were loaded with 5 mMe Authors
fluo4 AM for 15min in culture medium. Coverslips with cells were
transferred to a temperature-controlled chamber on an Olympus
Fluoview 1000 confocal microscope and washed with physiologic
salt solution (Tyrode’s) for 20 min for de-esterification of the dye.
Experiments were done at 35C. Linescan images were taken for
cells showing calcium cycling. Calcium transients were analyzed
usingClampfit software (Molecular Devices), andmeasures param-
eters such as amplitude, rise time from half amplitude to peak, and
decay time from peak to half amplitude were averaged for 5–10
beats for each cell.
Action Potential Measurement
For intracellular AP recording, both IRX4-2-MB-positive and -nega-
tive cells were transferred and cultured on 0.1% fibronectin-coated
glass bottom microwell dishes for 7 to 14 days. Next, the 35-mm
dishes were mounted on an inverted microscope (Olympus IX71)
and heated by a heating/cooling bath temperature controller
(DTC-200, Dagan Corporation). The cells were perfused with
Tyrode’s solution containing (mmol/L) 140 NaCl, 5.4 KC1, 1
MgCl2, 10 HEPES, 10 glucose, 1.8 CaCl2 (pH 7.4) with NAOH
37C. Glass microelectrodes were fabricated from borosilicate glass
(PG52151-4, World Precision Instruments) and pulled on a P-87
Flaming/Brown puller (Sutter Instrument Company). The tip resis-
tance of the microelectrode was 40–80 MU when filled with a
3 mol/L KCl solution. Intracellular recordings of membrane poten-
tial were performed using an EPC 7 amplifier (List Medical) in cur-
rent clamp mode at 37 ± 0.5C. The junction potential between
the microelectrode solution and the bath solution was adjusted to
zero, and the microelectrodes’ capacitance was compensated. Indi-
vidual cells were impaled with the sharp microelectrodes, and the
spontaneousAPswerefiltered at 10kHz anddigitized on a computer
at 10 kHz. APs were analyzed using Origin 6.0 software (Microcal).
MEA Recordings
Both IRX4-2-MB-positive and -negative cells were examined using
a MEA data acquisition system, a 64-channel Muse MEA system
(Axion Biosystems). Thirty thousand cells were plated onto fibro-
nectin-coated MEA chambers, and 3–5 days later, when cells
were stabilized, MEA recording was performed. After recording,
the data were analyzed using the AxIS software.
Statistical Analyses
All data were expressed as mean ± SEM. Kruskal-Wallis ANOVA test
was used for the statistical analysis for a small number of samples.
Values of p < 0.05 were considered to denote statistical significance.
All statistical analyses were conducted using SPSS 20.0 (SPSS).
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